Diabetes Research and Clinical Practice
Volume 74, Supplement 2 , Pages S112-S115, December 2006

Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes

Department of Pediatrics and General Clinical Research Center, Yale University School of Medicine, New Haven, CT, USA

Abstract 

Recent studies have shown that continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, provides a treatment option that can assist in the attainment of current goals of treatment in children and adolescents with type 1 diabetes (T1DM). In pediatric patients, CSII has been demonstrated to reduce both glycosylated hemoglobin levels and frequency of severe hypoglycemia, without sacrifices in safety, quality of life, or excessive weight gain, particularly in conjunction with the use of new insulin analogs and improvements in pump technology. Clinical studies of safety and efficacy of CSII in children are reviewed.

Keywords:  Continuous subcutaneous insulin infusion , Insulin pump , Type 1 diabetes , Diabetic children , HbAlc

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8227(06)70011-0

doi:10.1016/S0168-8227(06)70011-0

Diabetes Research and Clinical Practice
Volume 74, Supplement 2 , Pages S112-S115, December 2006

Article Tools